Activin receptor signaling: A potential therapeutic target for osteoporosis

Current Molecular Pharmacology

Volumn 5, Issue 2, 2012, Pages 195-204

  Lotinun, Sutada ^a   Scott Pearsall, R ^b   Horne, William C ^a   Baron, Roland ^a,c  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^b Acceleron Pharma Inc   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Activin; Follistatin; Inhibin; Osteoblast; Osteoclast; Osteoporosis

Indexed keywords

ACTIVIN; ACTIVIN A; ACTIVIN RECEPTOR; ACTIVIN RECEPTOR 1; ACTIVIN RECEPTOR 2; ACTIVIN RECEPTOR LIKE KINASE 1; ACTRIIA FC FUSION PROTEIN; ALK4 PROTEIN; ALK7 PROTEIN; BAMBI PROTEIN; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR; CRIPTO PROTEIN; FOLLISTATIN; FOLLISTATIN 288; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HORMONE RELEASE INHIBITING FACTOR; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; INHIBIN; INHIBIN A; INHIBIN B; MEMBRANE PROTEIN; MESSENGER RNA; PROTEIN SERINE THREONINE KINASE; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BLOOD SAMPLING; BONE TURNOVER; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; EVIDENCE BASED MEDICINE; EXTRACELLULAR MATRIX; GENE TARGETING; GROWTH INHIBITION; HAPLORHINI; HOMEOSTASIS; HUMAN; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

EID: 84861722759     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211205020195     Document Type: Article

References (75)

1. Marx, J. Coming to grips with bone loss. Science, 2004, 305, 1420-1422.
2. Durie, B.G.; Katz, M.; Crowley, J. Osteonecrosis of the jaws and bisphosphonates. N. Engl. J. Med., 2005, 353, 99-102.
3. Cartsos, V.M.; Zhu, S.; Zavras, A.I. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J. Am. Dent. Assoc., 2008, 139, 23-30.
4. Pazianas, M.; Miller, P.; Blumentals, W.A.; Bernal, M.; Kothawala, P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin. Ther., 2007, 29, 1548-1558.
5. Deal, C. Future therapeutic targets in osteoporosis. Curr. Opin. Rheumatol., 2009, 21, 380-385.
6. Ominsky, M.S.; Vlasseros, F.; Jolette, J.; Smith, S.Y.; Stouch, B.; Doellgast, G.; Gong, J.; Gao, Y.; Cao, J.; Graham, K.; Tipton, B.; Cai, J.; Deshpande, R.; Zhou, L.; Hale, M.D.; Lightwood, D.J.; Henry, A.J.; Popplewell, A.G.; Moore, A.R.; Robinson, M.K.; Lacey, D.L.; Simonet, W.S.; Paszty, C. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J. Bone Miner. Res., 2010, 25, 948-958.
7. Li, X.; Ominsky, M.S.; Warmingtom, K.S.; Morony, S.; Gong, J.; Cao, J.; Gao, Y.; Shalhoub, V.; Tipton, B.; Haldankar, R.; Chen, Q.; Winters, A.; Boone, T.; Geng, Z.; Niu, Q.T.; Ke, H.Z.; Kostenuik, P.J.; Simonet, W.S.; Lacey, D.L.; Paszty, C. Sclerostin antibody treatment increases bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res., 2009, 24, 574-588.
8. Hoeppner, L.H.; Secreto, F.J.; Westendorf, J.J. Wnt signaling as a therapeutic target for bone diseases. Expert. Opin. Ther. Targets, 2009, 13, 455-496.
9. Nicks, K.M.; Perrien, D.S.; Akel, N.S.; Suva, L.J.; Gaddy, D. Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin. Mol. Cell Endocrinol., 2009, 310, 11-20.
10. Perrien, D.S.; Achenbach, S.J.; Bledsoe, S.E.; Walser, B.; Suva, L.J.; Khosla, S.; Gaddy, D. Bone turnover across the menopause transition: correlations with inhibins and follicle-stimulating hormone. J. Clin. Endocrinol. Metab., 2006, 91, 1848-1854.
11. Pearsall, R.S.; Canalis, E.; Cornwall-Brady, M.; Underwood, K.W.; Haigis, B.; Ucran, J.; Kumar, R.; Pobre, E.; Grinberg, A.; Werner, E.D.; Glatt, V.; Stadmeyer, L.; Smith, D.; Seehra, J.; Bouxsein, M.L. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc. Natl. Acad. Sci. USA, 2008, 105, 7082-7087.
12. Fajardo, R.J.; Manoharan, R.K.; Pearsall, R.S.; Davies, M.V.; Marvell, T.; Monnell, T.E.; Ucran, J.A.; Pearsall, A.E.; Khanzode, D.; Kumar, R.; Underwood, K.W.; Roberts, B.; Seehra, J.; Bouxsein, M.L. Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis). Bone, 2010, 46, 64-71.
13. Lotinun, S.; Pearsall, R.S.; Davies, M.V.; Marvell, T.H.; Monnell, T.E.; Ucran, J.; Fajardo, R.J.; Kumar, R.; Underwood, K.W.; Seehra, J.; Bouxsein, M.L.; Baron, R. A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone, 2010, 46, 1082-1088.
14. Ruckle, J.; Jacobs, M.; Kramer, W.; Pearsall, A.E.; Kumar, R.; Underwood, K.W.; Seehra, J.; Yang, Y.; Condon, C.H.; Sherman, M.L. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J. Bone Miner. Res., 2009, 24, 744-752.
15. Tsuchida, K. Activins, myostatin and related TGF-beta family members as novel therapeutic targets for endocrine, metabolic and immune disorders. Curr. Drug Targets Immune. Endocr. Metabol. Disord., 2004, 4, 157-66.
16. Shav-Tal, Y.; Zipori, D. The role of activin a in regulation of hemopoiesis. Stem Cells, 2002, 20, 493-500.
17. Rodgarkia-Dara, C.; Vejda, S.; Erlach, N.; Losert, A.; Bursch, W.; Berger, W.; Schulte-Hermann, R.; Grusch, M. The activin axis in liver biology and disease. Mutat. Res., 2006, 613, 123-137.
18. Chang, H.; Brown, C.W.; Matzuk, M.M. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr. Rev., 2002, 23, 787-823.
19. Vale, W., Rivier, C., Hsueh, A., Campen, C., Meunier, H., Bicsak, T., Vaughan, J., Corrigan, A., Bardin, W., Sawchenko, P., Petraglia, F., Yu, J., Plotsky, P., Spiess, J., Rivier, J. Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog. Horm. Res., 1988, 44, 1-34.
20. Massague, J. The transforming growth factor-β family. Annu. Rev. Cell Biol, 1990, 6, 597-641.
21. Deli, A.; Kreidl, E.; Santifaller, S.; Trotter, B.; Seir, K.; Berger, W.; Schulte-Hermann, R.; Rodgarkia-Dara, C.; Grusch, M. Activins and activin antagonists in hepatocellular carcinoma. World J. Gastroenterol., 2008, 14, 1699-1709.
22. Oda, S.; Nishimatsu, S.; Murakami, K.; Ueno, N. Molecular cloning and functional analysis of a new activin beta subunit: a dorsal mesoderm-inducing activity in Xenopus. Biochem. Biophys. Res. Commun., 1995, 210, 581-588.
23. Wang, H.; Tsang, B.K. Nodal signalling and apoptosis. Reproduction, 2007, 133, 847-853.
24. Peng, C. The TGF-beta superfamily and its roles in the human ovary and placenta. J. Obstet. Gynaecol. Can., 2003, 25, 834-844.
25. Miyazawa, K.; Shinozaki, M.; Hara, T.; Furuya, T.; Miyazon, K. Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells, 2002, 7, 1191-1204.
26. Tsuchida, K.; Nakatani, M.; Hitachi, K.; Uezumi, A.; Sunada, Y.; Ageta, H.; Inokuchi, K. Activin signaling as an emerging target for therapeutic interventions. Cell Commun. Signal., 2009, 18, 7-15.
27. Zhang, L.; Wang, W.; Hayashi, Y.; Jester, J.V.; Birk, D.E.; Gao, M.; Liu, C.Y.; Kao, W.W.; Karin, M.; Xia, Y. A role for MEK kinase 1 in TGF-beta/activin-induced epithelium movement and embryonic eyelid closure. EMBO J., 2003, 22, 4443-4454.
28. Zhu, W.; Xu, P.; Cuascut, F.X.; Hall, A.K.; Oxford, G.S. Activin acutely sensitizes dorsal root ganglion neurons and induces hyperalgesia via PKC-mediated potentiation of transient receptor potential vanilloid I. J. Neurosci., 2007, 27, 13770-13780.
29. Bao, Y.L.; Tsuchida, K.; Liu, B.; Kurisaki, A.; Matsuzaki, T.; Sugino, H. Synergistic activity of activin A and basic fibroblast growth factor on tyrosine hydroxylase expression through Smad3 and ERK1/ERK2 MAPK signaling pathways. J. Endocrinol., 2005, 184, 493-504.
30. de Guise, C.; Lacerte, A.; Rafiei, S.; Reynaud, R.; Roy, M.; Brue, T.; Lebrun, J.J. Activin inhibits the human Pit-1 gene promoter through the p38 kinase pathway in a Smad-independent manner. Endocrinology, 2006, 147, 4351-4362.
31. Hirota, M.; Watanabe, K.; Hamada, S.; Sun, Y.; Strizzi, L.; Mancino, M.; Nagaoka, T.; Gonzales, M.; Seno, M.; Bianco, C.; Salomon, D.S. Smad2 functions as a co-activator of canonical Wnt/beta-catenin signaling pathway independent of Smad4 through histone acetyltransferase activity of p300. Cell Signal., 2008, 20, 1632-1641.
32. Do, T.V.; Kubba, L.A.; Antenos, M.; Rademaker, A.W.; Sturgis, C.D.; Woodruff, T.K. The role of activin A and Akt/GSK signaling in ovarian tumor biology. Endocrinology, 2008, 149, 3809-3816.
33. Sugatani, T.; Alvarez, U.M.; Hruska, K.A. Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. J. Cell Biochem., 2003, 90, 59-67.
34. Lebrun, J.J.; Takabe, K.; Chen, Y.; Vale, W. Roles of pathwayspecific and inhibitory Smads in activin receptor signaling. Mol. Endocrinol., 1999, 13, 15-23.
35. Ling, N.; Ying, S.Y.; Ueno, N.; Esch, F.; Denoroy, L.; Guillemin, R. Isolation and partial characterization of a Mr 32,000 protein with inhibin activity from porcine follicular fluid. Proc. Natl. Acad. Sci. USA, 1985, 82, 7217-7221.
36. Mathews, L.S.; Vale, W.W. Expression cloning of an activin receptor, a predicted transmembrane serine kinase. Cell, 1991, 65, 973-982.
37. Stenvers, K.L.; Findlay, J.K. Inhibins: from reproductive hormones to tumor suppressors. Trends Endocrinol. Metab., 2010, 21, 174-180.
38. Farnworth, P.G.; Stanton, P.G.; Wang, Y.; Escalona, R.; Findlay, J.K.; Ooi, G.T. Inhibins differentially antagonize activin and bone morphogenetic protein action in a mouse adrenocortical cell line. Endocrinology, 2006, 147, 3462-3471.
39. Onichtchouk, D.; Chen, Y.G.; Dosch, R.; Gawantka, V.; Delius, H.; Massagué, J.; Niehrs, C. Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature, 1999, 401, 480-485.
40. Kelber, J.A.; Shani, G.; Booker, E.C.; Vale, W.W.; Gray, P.C. Cripto is a noncompetitive activin antagonist that forms analogous signaling complexes with activin and nodal. J. Biol. Chem., 2008, 283, 4490-4500.
41. Shen, M.M.; Schier, A.F. The EGF-CFC gene family in vertebrate development. Trends Genet., 2000, 16, 303-309.
42. Iemura, S.; Yamamoto, T.S.; Takagi, C.; Uchiyama, H.; Natsume, T.; Shimasaki, S.; Sugino, H.; Ueno, N. Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo. Proc. Natl. Acad. Sci. USA, 1998, 95, 9337-9342.
43. Gamer, L.W.; Wolfman, N.M.; Celeste, A.J.; Hattersley, G.; Hewick, R.; Rosen, V. A novel BMP expressed in developing mouse limb, spinal cord, and tail bud is a potent mesoderm inducer in Xenopus embryos. Dev. Biol., 1999, 208, 222-232.
44. Nakamura, T.; Sugino, K.; Titani, K.; Sugino, H. Follistatin, an activin-binding protein, associates with heparan sulfate chains of proteoglycans on follicular granulosa cells. J. Biol. Chem., 1991, 266, 19432-19437.
45. Inouye, S.; Guo, Y.; DePaolo, L.; Shimonaka, M.; Ling, N.; Shimasaki, S. Recombinant expression of human follistatin with 315 and 288 amino acids: chemical and biological comparison with native porcine follistatin. Endocrinology, 1991, 129, 815-822.
46. Sugino, K.; Kurosawa, N.; Nakamura, T.; Takio, K.; Shimasaki, S.; Ling, N.; Titani, K.; Sugino, H. Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell. J. Biol. Chem., 1993, 268, 15579-15587.
47. Schneyer, A.L.; Wang, Q.; Sidis, Y.; Sluss, P.M. Differential distribution of follistatin isoforms: application of a new FS315-specific immunoassay. J. Clin. Endocrinol. Metab., 2004, 89, 5067-5075.
48. Mukherjee, A.; Sidis, Y.; Mahan, A.; Raher, M.J.; Xia, Y.; Rosen, E.D.; Bloch, K.D.; Thomas, M.K.; Schneyer, A.L. FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults. Proc. Natl. Acad. Sci. USA, 2007, 104, 1348-1353.
49. Sidis, Y.; Mukherjee, A.; Keutmann, H.; Delbaere, A.; Sadatsuki, M.; Schneyer, A. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology, 2006, 147, 3586-3597.
50. Brown, C.W.; Houston-Hawkins, D.E.; Woodruff, T.K.; Matzuk, M.M. Insertion of Inhbb into the Inhba locus rescues the Inhba-null phenotype and reveals new activin functions. Nat. Genet., 2000, 25, 453-457.
51. Matzuk, M.M.; Kumar, T.R.; Vassalli, A.; Bickenbach, J.R.; Roop, D.R.; Jaenisch, R.; Bradley, A. Functional analysis of activins during mammalian development. Nature, 1995, 374, 354-356.
52. Ogawa, Y.; Schmidt, D.K.; Nathan, R.M.; Armstrong, R.M.; Miller, K.L.; Sawamura, S.J.; Ziman, J.M.; Erickson, K.L.; de Leon, E.R.; Rosen, D.M.; Seyedin, S.M.; Glaser, C.B.; Chang, R.; Corrigan, A.Z.; Vale, W. Bovine bone activin enhances bone morphogenetic protein-induced ectopic bone formation. J. Biol. Chem., 1992, 267, 14233-14237.
53. Centrella, M.; McCarthy, T.L.; Canalis, E. Activin-A binding and biochemical effects in osteoblast-enriched cultures from fetal-rat parietal bone. Mol. Cell. Biol., 1991, 11, 250-258.
54. Sakai, R.; Fujita, S.; Horie, T.; Ohyama, T.; Miwa, K.; Maki, T.; Okimoto, N.; Nakamura, T.; Eto, Y. Activin increases bone mass and mechanical strength of lumbar vertebrae in aged ovariectomized rats. Bone, 2000, 27, 91-96.
55. Sakai, R.; Miwa, K.; Eto, Y. Local administration of activin promotes fracture healing in the rat fibula fracture model. Bone, 1999, 25, 191-196.
56. Oue, Y.; Kanatani, H.; Kiyoki, M.; Eto, Y.; Ogata, E.; Matsumoto, T. Effect of local injection of activin A on bone formation in newborn rats. Bone, 1994, 15, 361-366.
57. Hashimoto, M.; Shoda, A.; Inoue, S.; Yamada, R.; Kondo, T.; Sakurai, T.; Ueno, N.; Muramatsu, M. Functional regulation of osteoblastic cells by the interaction of activin-A with follistatin. J. Biol. Chem., 1992, 267, 4999-5004.
58. Ikenoue, T.; Jingushi, S.; Urabe, K.; Okazaki, K.; Iwamoto, Y. Inhibitory effects of activin-A on osteoblast differentiation during cultures of fetal rat calvarial cells. J. Cell. Biochem., 1999, 75, 206-214.
59. Eijken, M.; Swagemakers, S.; Koedam, M.; Steenbergen, C.; Derkx, P.; Uitterlinden, A.G.; van der Spek, P.J.; Visser, J.A.; de Jong, F.H.; Pols, H.A.; van Leeuwen, J.P. The activin A-follistatin system: potent regulator of human extracellular matrix mineralization. FASEB J., 2007, 21, 2949-2960.
60. Gaddy-Kurten, D.; Coker, J. K.; Abe, E.; Jilka, R. L.; Manolagas, S. C. Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures. Endocrinology, 2002, 143, 74-83.
61. Inoue, S.; Nomura, S.; Hosoi, T.; Ouchi, Y.; Orimo, H.; Muramatsu, M. Localization of follistatin, an activin-binding protein, in bone tissues. Calcif. Tissue Int., 1994, 55, 395-397.
62. Hashimoto, M.M.; Shoda, A.; Inoue, S.; Yamada, R.; Kondo, T.; Sakurai, T.; Ueno, N.; Muramatsu, M. Functional regulation of osteoblastic cells by the interaction of activin-A with follistatin. J. Biol. Chem., 1992, 267, 4999-5004.
63. Funaba, M.; Ogawa, K.; Murata, T.; Fujimura, H.; Murata, E.; Abe, M.; Takahashi, M.; Torii, K. Follistatin and activin in bone: Expression and localization during endochondral bone development. Endocrinology, 1996, 137, 4250-4259.
64. Matzuk, M.M.; Lu, N.; Vogel, H.; Sellheyer, K.; Roop, D.R.; Bradley, A. Multiple defects and perinatal death in mice deficient in follistatin. Nature, 1995, 374, 360-363.
65. Guo, Q., Kumar, T. R., Woodruff, T., Hadsell, L. A., DeMayo, F. J., Matzuk, M. M. Overexpression of mouse follistatin causes reproductive defects in transgenic mice. Mol. Endocrinol., 1998, 12, 96-106.
66. Yu, J.; Shao, L.E.; Lemas, V.; Yu, A.L.; Vaughan, J.; Rivier, J.; Vale, W. Importance of FSH-releasing protein and inhibin in erythrodifferentiation. Nature, 1987, 330, 765-767.
67. Fujimoto, K.; Kawakita, M.; Kato, K.; Yonemura, Y.; Masuda, T.; Matsuzaki, H.; Hirose, J.; Isaji, M.; Sasaki, H.; Inoue, T. Purification of megakaryocyte differentiation activity from a human fibrous histiocytoma cell line: N-terminal sequence homology with activin A. Biochem. Biophys. Res. Commun., 1991, 174, 1163-1168.
68. Broxmeyer, H.E.; Lu, L.; Cooper, S.; Schwall, R.H.; Mason, A.J.; Nikolics, K. 1988 Selective and indirect modulation of human multipotential and erythroid hematopoietic progenitor cell proliferation by recombinant human activin and inhibin. Proc. Natl. Acad. Sci. USA, 1988, 85, 9052-9056.
69. Perrien, D.S.; Achenbach, S.J.; Bledsoe, S.E.; Walser, B.; Suva, L.J.; Khosla, S.; Gaddy, D. Bone turnover across the menopause transition: correlations with inhibins and follicle-stimulating hormone. J. Clin. Endocrinol. Metab., 2006, 91, 1848-1854.
70. Perrien, D.S.; Akel, N.S.; Edwards, P.K.; Carver, A.A.; Bendre, M.S.; Swain, F.L.; Skinner, R.A.; Hogue, W.R.; Nicks, K.M.; Pierson, T.M.; Suva, L.J.; Gaddy, D. Inhibin A is an endocrine stimulator of bone mass and strength. Endocrinology, 2007, 148, 1654-1665.
71. Murase, Y.; Okahashi, N.; Koseki, T.; Itoh, K.; Udagawa, N.; Hashimoto, O.; Sugino, H.; Noguchi, T.; Nishihara T. Possible involvement of protein kinases and Smad2 signaling pathways on osteoclast differentiation enhanced by activin A. J. Cell. Physiol., 2001, 188, 236-242.
72. Vallet, S.; Mukherjee, S.; Vaghela, N.; Hideshima, T.; Fulciniti, M.; Pozzi, S.; Santo, L.; Cirstea, D.; Patel, K.; Sohani, A.R.; Guimaraes, A.; Xie, W.; Chauhan, D.; Schoonmaker, J.A.; Attar, E.; Churchill, M.; Weller, E.; Munshi, N.; Seehra, J.S.; Weissleder. R.; Anderson, K.C.; Scadden, D.T.; Raje, N. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc. Natl. Acad. Sci. USA. 2010, 107, 5124-5129.
73. Kang, H.Y.; Huang, H.Y.; Hsieh, C.Y.; Li, C.F.; Shyr, C.R.; Tsai, M.Y.; Chang, C.; Chuang, Y.C.; Huang, K.E. Activin A enhances prostate cancer cell migration through activation of androgen receptor and is overexpressed in metastatic prostate cancer. J. Bone Miner. Res., 2009, 24, 1180-1193.
74. Lee, S.J.; Reed, L.A.; Davies, M.V.; Girgenrath, S.; Goad, M.E.; Tomkinson, K.N.; Wright, J.F.; Barker, C.; Ehrmantraut, G.; Holmstrom, J.; Trowell, B.; Gertz, B.; Jiang, M.S.; Sebald, S.M.; Matzuk, M.; Li, E.; Liang, L.F.; Quattlebaum, E.; Stotish, R.L.; Wolfman, N.M. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci. USA, 2005, 102, 18117-18122.
75. Chantry, A.D.; Heath, D.; Mulivor, A.W.; Pearsall, R.S.; Baud'huin, M; Coulton, L.; Evans, H.; Abdul, N.; Werner, E.D.; Bouxsein, M.L.; Key, M.L.; Seehra, J.; Arnett, T.R.; Vanderkerken, K.; Croucher, P. Inhibiting activin-A signaling stimulates bone formation and prevents cancer induced bone destruction in vivo. J. Bone Miner. Res., 2010, 25, 2633-2646.